ACE and congestive heart failure: Nonetheless, the utility of the ACE I/D polymorphism for pharmacogenetic risk stratification in CHF patients remains contentious, which may be explained, in part, by an anticipated small impact of this polymorphism on ACEI efficacy, and by the fact that published results have been limited by small study populations [22, 25, 26].